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ABSTRACT
Introduction: Inverse psoriasis is a rare form of
psoriasis that affects between 3% and 7% of the
patients with psoriasis. It can comprise genital
skin folds as part of genital psoriasis, and it is
one of the most commonly seen dermatoses of
this area. There are few evidence-based studies
about the treatment of intertriginous psoriasis
involving genital skin folds.
Case Presentation: The authors present a
42-year-old female patient with erythematous
plaques in the vulva, groin, and perianal region.
The patient had previously received a broad
range of topical and systemic therapies that had
to be discontinued due to ineffectiveness or side
effects. She was treated with 100 mg dapsone
daily for 10 months, showing a significant
improvement of her cutaneous and mucous
lesions. Complete clearance of psoriatic lesions
was observed after 4 weeks of treatment. She has
remained in remission for up to 2 years, using
only topical therapy with tacrolimus 0.1% and
calcipotriol.
Discussion: Genital psoriasis is a skin disease
that causes great discomfort. It is important to
include examination of the genital region and
to adopt this conduct in daily clinical practice.
Research in this field is still poor, making
no discrimination between flexural and genital
psoriasis, and is based on case series and expert
opinion; therefore, empirical recommendations
for the treatment of genital psoriasis remain.
Dapsone has been shown to be an effective and
convenient alternative for the treatment of
inverse psoriasis in genital skin folds, which
can provide effective control of the disease.
Further studies are required to determine the
efficacy and safety of current therapies, and to
decide whether dapsone therapy should be
considered in the management of this form of
psoriasis when topical and other systemic
agents are not effective.
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INTRODUCTION
Psoriasis is a chronic inflammatory skin disease
involving the epidermis. It is characterized by
scaly erythematous plaques and compromise of
different body zones, usually with pruritus, and
has a significant negative impact on quality of
life [1]. The worldwide prevalence of psoriasis is
estimated to be 2% [2–4]. Inverse psoriasis, also
known as intertriginous or skin-fold psoriasis, is
a form of psoriasis that presents itself as
erythematous plaques with poor or non-
desquamation in skin flexion folds [5]. It
affects between 3% and 7% of the patients
with psoriasis; however, the actual incidence is
still unknown [6]. Inverse psoriasis can
compromise genital skin folds as part of
genital psoriasis, and it is one of the most
commonly seen dermatoses of this area in both
females and males [1]. In most cases, genital
psoriasis can accompany plaque psoriasis
lesions on other parts of the body, but it has
also been reported as being isolated to the
genital skin; this form of presentation is rare
and occurs in only 2–5% of psoriatic patients
[7, 8]. Local conditions of intertriginous areas,
such as warmth, moisture, and friction, make it
susceptible to maceration, fissuring, constant
irritation, and absence of scaling, which induces
the modified clinical appearance of psoriasis
in flexion folds when compared with classical
characteristics of psoriasis vulgaris. As a result,
differential diagnosis with fungal and sexually
transmitted diseases becomes difficult, and
resistance to treatment is higher than in other
skin zones. Treatment options are limited and
difficult to determine because of the lack of
evidence-based data, high sensitivity of the area
involved, and increased penetration of topical
treatments in this vulnerable zone, making it a
challenge for the clinician.
There are few evidence-based studies on the
treatment of inverse psoriasis involving genital
flexion folds, and data reported related to the
efficacy and safety are, so far, extremely limited
and only supported by expert opinion (level of
evidence 5 and recommendation class D) [1].
The evidence-based recommendations suggest
the use of weaker topical corticosteroids as a
first-line treatment, and vitamin D preparations
or tar-based treatments as second-line options
[1]. There are reported cases that have used
dapsone (Aczone, Allergan, Marlow, UK) as a
treatment option, which has shown great
effectiveness and complete remission after
4 weeks of treatment [9]. The case reported in
this article is of a female patient with inverse
and genital psoriasis successfully treated with
dapsone.
CASE PRESENTATION
A 42-year-old female patient, without co-morbid
conditions, presented with clinical
manifestations of 2 years duration,
characterized by extensive erythematous and
exudative plaques in the groin and vulva, lately
appearing intergluteal and perianal
intertriginous plaques, and associated with
secondary recurrent vulvovaginitis, which had
an immensely negative impact on her quality of
life and psychosexual wellbeing (Figs. 1, 2).
The patient had previously received a broad
range of topical and systemic therapies that had
to be discontinued due to ineffectiveness or side
effects. A genital skin biopsy was performed,
with the results showing superficial interstitial
psoriasiform spongiotic and perivascular
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dermatitis, with signs of lichenification. The
patient started treatment with 20 mg
methotrexate weekly. Over the next few
months the patient had irregular clinical
progression with partial therapeutic response,
and in addition, presented with recurrent
episodes of urinary tract infections. After
4 months of treatment, the patient was
changed to 500 mg mycophenolate mofetil
(CellCept, Roche, Welwyn Garden City, UK)
twice a day for 2 months, which induced slowly
improving clinical results. Due to financial
issues and after written informed consent from
the patient was obtained, treatment was
changed to 100 mg dapsone daily, which
produced an excellent response and significant
improvement, with complete clearance of
cutaneous and mucous psoriatic lesions after
1 month of oral treatment, which was
maintained over a period of 10 months of
therapy. The patient has remained in
remission for up to 2 years after treatment,
using only topical therapy with tacrolimus
0.1% and calcipotriol (Figs. 3, 4). No adverse
events were recorded.
DISCUSSION
Scientific evidence shows that involvement of
the genital skin occurs in 29–40% of patients
Fig. 1 Erythematous and exudative plaques in perianal
fold
Fig. 2 Intensive erythematous and exudative plaques in
the vulvar area, associated with vaginal ﬂow
Fig. 3 Complete clearance of cutaneous and mucous
psoriatic lesions 2 years after systemic therapy. The patient
remained on topical treatment only (tacrolimus 0.1% and
calcipotriol)
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with psoriasis [10–14]. When there is inverse
psoriasis, the genital area is usually involved in
up to 79% of the patients [6]. In dermatological
consults for chronic symptomatic vulvar
disorders, 2% of the cases are caused by
psoriasis [15]. Articles that analyzed non-
neoplastic biopsies of vulva and vagina
reported that 1.8–6.9% of the samples were
histologically diagnosed as vulvar psoriasis
[16, 17]. In children, vulvar psoriasis was the
third most common cutaneous condition
among prepubertal girls (9.5–17% of cases)
[18, 19]. In males, genital psoriasis of the penis
was diagnosed in 3% of patients with alterations
of penile skin and genital skin folds [20]. The
etiology of inverse and genital psoriasis is still
unknown and further studies are needed in
order to clarify these diseases [1]. However, as
treatment for psoriasis vulgaris is also effective
for genital psoriasis, it seems to have a
pathophysiology similar to plaque psoriasis in
other skins zones. The pathophysiology
involves an alteration in the activation of
CD4? and CD8? T-cells and an anomalous
proliferation and differentiation of
keratinocytes. It is still not understood as to
what causes the disease to commence in this
particular zone; the anomalous proliferation
and differentiation of keratinocytes suggests
that maybe the Koebner phenomenon of
constant local mechanical and chemical
irritation of flexion folds possibly perpetuates
the process [21].
Inverse psoriasis in genital skin folds usually
presents itself as erythematous, irregular, well-
demarcated, thin, and often symmetrical
plaques in the vulva and vagina, with poor or
non-desquamation because of the local
conditions, as discussed earlier [5, 6, 22–25]
and lacks the typical scaling of plaque psoriasis
in other skin zones. However, minimal scaling
can be seen on the more keratinized regions of
the genital skin [26, 27]. The mucosa of the
vagina can also be compromised as part of
genital psoriasis, showing exudative and bright
erythematous plaques, this compromise is less
frequently diagnosed in women than in men
[26, 28]. Lesions may also have fissures,
maceration, and rhagades, and may be
accompanied with pruritus, pain, or burning
sensation, causing irritation and scratching,
producing more plaques through the Koebner
phenomenon and local lichenification;
therefore, perpetuating the process. Other
conditions may also cause irritation, such as
sexual intercourse, urine, feces, underwear,
clothes, and local infections [27]. Genital
psoriasis usually does not produce scarring.
However, one case report of two patients
described atrophic scarring of the labia
minora, mimicking the scarring caused by
genital lichen sclerosus [29]. Another
condition rarely seen is genital compromise
with pustular psoriasis as part of a localized or
generalized pustular process, but this
complication has only been reported in men
[1, 9, 30, 31]. Genital psoriasis can affect not
only prepubertal girls, but also small children
presenting localized or disseminated psoriatic
eruptions in the napkin and genital area [32].
Fig. 4 Perineal fold with complete clearance of psoriasis
plaques 2 years after systemic therapy
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Reports showed that 13% of children with
psoriasis had psoriatic napkin eruptions with
dissemination, whereas 4% had a localized
psoriatic napkin eruption [32], with anogenital
psoriasis occurring four-times more often in
children over 2 years old than in children under
2 years of age [32].
Diagnosis is based on clinical background,
symptoms, clinical signs, and the appearance of
skin lesions in the genital area or elsewhere in the
body [19, 23, 33, 34]. However, in cases where
genital lesions are the only clinical finding, skin
biopsy might be an option, showing the
same classical histopathological characteristics
of non-genital plaque psoriasis, such as
Kogoj’s and Munro-Sabouraud’s collections of
neutrophils, thickening of the Malpighian layer,
hypogranulosis, hyperkeratosis, parakeratosis,
and elongation of the papillae [3, 5, 16, 17, 35],
but with the slight difference that this findings
may be less evident in vulvar and penile psoriatic
lesions [17, 29].
There are numerous therapeutic options for
treating psoriasis, which is a therapeutic
challenge when it is limited to intertriginous
areas such as genital skin flexion folds. So far,
there are few evidence-based studies regarding
the treatment of inverse psoriasis involving
genital flexion folds, and data related to
efficacy and safety are extremely limited and
only supported by expert opinion (level of
evidence 5 and recommendation class D) [1].
In fact, only six casuistic reports and one open-
label study have described the effects of
therapies used [1], and 24 articles, selected by
the only systematic literature review available,
reflected the opinion of experts on the preferred
treatment for genital psoriasis [1].
Evidence-based recommendations for genital
psoriasis indicate the use of short-term topical
low-to-medium power corticoids as a first-line
treatment option, which can be combined with
vitamin D analogs or mild tar preparations [1].
Experts advise the intermittent, short-term use of
moderate-to-potent corticosteroids followed
by a subsequent gradual shift towards a weaker
corticosteroid in cases where weak corticosteroids
seem insufficiently potent to induce a response;
these treatments should always be monitored for
possible local atrophic effects [35–37]. Mild
topical coal-tar preparations are the second
most advised topical therapy in adults and the
first choice for children with napkin plaque
psoriasis [1], and are used as an individual
topical therapy or combined/alternated therapy
with topical steroids [36, 37]. It should be noted
that secondary effects have been reported, such
as irritation or folliculitis [1, 24, 28, 38]. The use
of tar preparations with a steroid preparation has
been recommended to reduce irritation [27]. In
children, it can also be used mixed with zinc
oxide [39, 40]. Topical treatment of vitamin D
analogs (such as calcipotriol) has also shown
benefits either alone as monotherapy or
combined with steroid preparations (to reduce
the irritation that these analogs cause), especially
in male patients [1, 33]. The use of topical
immunomodulator agents, such as tacrolimus
or 1% pimecrolimus cream, have shown benefits
for long-term therapies [41, 42], and should be
regarded as third-line treatment options [1, 24],
but patients should be monitored periodically for
possible complications, such as local irritation,
stinging, irritant or allergic contact dermatitis,
candidiasis, and/or (re)activation of viral skin
infections [1]. Topical cyclosporine has also
shown beneficial effects when used in genital
psoriasis of the glans, penis, and prepuce [43]. If
concurrent bacterial or fungal infections are
present, they should be treated with topical
antibiotics or antifungal drugs, and local
irritation should be reduced with mild
emollients in order to eliminate the possible
Koebner effect [1]. If vulvar plaques are resistant
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to treatment, a biopsy should be carried out to
rule out malignancy [44].
Systemic therapies (methotrexate,
cyclosporine, oral retinoids, or biological drugs)
are used for severe or extensive psoriasis, or when
there is a significant negative impact on quality
of life [1, 45, 46], but they are not used as
common practice for isolated genital psoriasis
[1]. Local treatment with topical dithranol
(anthralin) and tazarotene should be avoided in
the genital area [1, 24, 27]. Laser therapies
(excimer, continuous carbon dioxide,
erbium, pulsed dye laser) and UV phototherapy
are commonly used for localized skin
plaque psoriasis [47–50], except for YAG
(yttrium–aluminum–garnet) laser, which has
been shown not to improve localized plaque
psoriasis [51]. However, these treatments are not
recommended for genital psoriasis. Moreover,
it has been suggested that these modalities
should be avoided in inverse psoriasis with
compromised genital skin folds [1].
Nonstandard and off-label therapies for
psoriasis should be chosen when there is
resistance to conventional therapies, when
there are multiple side effects, in unusual
presentations, or in cases with specific
comorbidities [45, 46]. One of these therapies is
dapsone, a sulfone initially used for the
treatment of leprosy. Nowadays, its use has
extended to other inflammatory dermatoses
[46]. It has antibiotic, anti-inflammatory, and
immunomodulatory properties [46]. MacMillan
and Champion first reported the use of dapsone
as a treatment for psoriasis in an adult with
treatment-resistant generalized pustular
psoriasis [52]. Since then it has been used in
cases of pustular psoriasis, especially in children
[53–59]. Side effects are dose-dependent,
hemolysis and methemoglobinemia being the
most frequently reported, and more rarely
reported agranulocytosis, hypersensitivity
syndrome, and peripheral neuropathy [46, 60].
The recommended dosing of dapsone in
childhood pustular psoriasis is 1 mg/kg daily,
whereas in adults with dermatitis herpetiformis a
starting dose of 50 mg daily is recommended,
which can be increased, as tolerated, up to
300 mg daily or higher if necessary. The dosage
should be reduced to a lower maintenance dose if
possible [46]. Dapsone has been chosen by
physicians as a treatment option for genital
psoriasis; this type of therapeutic regimen was
first described in 2008 in a case report by Singh
and Thappa [9]. They used dapsone 100 mg daily
in a male patient with pustular psoriasis of the
penis, the lesions subsided completely after
4 weeks of treatment, similar to the results
obtained in the present case. Regarding
monitoring, it is recommended that complete
blood cell and platelet counts are undertaken
weekly for 4 weeks, monthly for 6 months, and
then every 6 months, and liver function tests and
total bilirubin are performed periodically [46].
In conclusion, genital psoriasis is a skin
disease that causes great discomfort. It is
important to include an examination of the
genital region and to adopt this conduct in
daily clinical practice. Thus far, research in this
field is poor, making no discrimination between
flexural and genital psoriasis, and is based on
case series and expert opinion; therefore,
recommendations for the treatment of genital
psoriasis are empirical. Dapsone has been
shown to be an effective and convenient
alternative for the treatment of inverse
psoriasis in genital skin folds, which can
provide effective control of the disease.
Further studies are required to determine the
efficacy and safety of current therapies, and to
decide whether this therapy should be
considered in the management of this form of
psoriasis when topical and other systemic
agents are not effective.
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